Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
GLP-1 Comparison · May 4, 2026 · Prices Verified
Mounjaro vs Rybelsus 2026: Cost, A1C, Weight & Verdict
Published:
Written by The RX Index Editorial Team
Last verified: · FDA labels via DailyMed · Pricing verified · See methodology
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We earn affiliate income from some links on this page. That income does not change which medication we recommend or which clinical data we report.
Bottom line up front
Most adults with type 2 diabetes who can use a weekly injection should discuss Mounjaro (tirzepatide) first if the priority is lowering A1C and body weight. Rybelsus (oral semaglutide) is the better fit if needles are a hard no, you can keep a strict morning routine, or your doctor wants to discuss its FDA-approved indication for cutting cardiovascular risk in high-risk type 2 diabetes. Starting May 4, 2026, Rybelsus is being reformulated and relaunched in the US as Ozempic® tablets — the active ingredient is identical. If your goal is weight loss only — not diabetes — you are in the wrong comparison; we will route you to the right FDA-approved option in two minutes.
Quick verdict at a glance
| If this is you | Better starting point |
|---|---|
| Adult with T2D — want maximum A1C and weight effect | Mounjaro |
| Adult with T2D — needles are a dealbreaker | Rybelsus / Ozempic tablets |
| Adult with T2D + high cardiovascular risk | Rybelsus / Ozempic tablets (CV-risk indication) |
| Cost is the main blocker, you want the oral path | Ozempic tablets via NovoCare ($149–$299/mo) |
| Goal is weight loss, not diabetes | Zepbound, Wegovy, or Foundayo — not these two |
| Currently on Rybelsus and worried about the brand change | Keep your current prescription. Read the next section. |
Not sure which column fits you?
Take our free 60-second quiz — it asks about your goal, insurance, needle preference, and budget, then returns a specific FDA-approved medication and the telehealth path that actually carries it.
Take the 60-second GLP-1 path quiz →What is happening with Rybelsus in the US
Answer capsule
Starting May 4, 2026, Novo Nordisk is introducing Ozempic® tablets in the US as a reformulated oral semaglutide option for adults with type 2 diabetes. Current Rybelsus patients should keep taking their medication as directed and talk with their prescriber about transitioning at the next refill. Rybelsus will continue to be marketed outside the US.
If you are a current Rybelsus patient reading this — please do not switch on your own. Keep taking what you have. The active ingredient in your tablet is the same. The new tablet is smaller, has a new coating, and absorbs better, which is why the milligram numbers dropped on the new version.
Dose mapping: Rybelsus → Ozempic tablets
The two products are not interchangeable on a milligram-to-milligram basis. Your prescriber should set the timing of any switch.
| Old Rybelsus dose (US) | New Ozempic tablets dose (US) | NovoCare cash-pay price |
|---|---|---|
| 3 mg/day (initiation, 30 days) | 1.5 mg/day (initiation, 30 days) | $149/month |
| 7 mg/day (maintenance) | 4 mg/day (maintenance) | $199/month |
| 14 mg/day (high dose) | 9 mg/day (high dose) | $299/month |
Per the FDA prescribing information on DailyMed, patients on Rybelsus 7 mg may transition to Ozempic tablets 4 mg after 30 days, and patients on Rybelsus 14 mg may transition to Ozempic tablets 9 mg after 30 days. The label says not to switch during the initiation phase unless your prescriber directs it.
- •The new Ozempic tablets cash-pay offer through NovoCare Pharmacy is for self-pay patients only. Government beneficiaries (Medicare, Medicaid, TRICARE, VA) are excluded, per Novo Nordisk's May 1 announcement.
- •Novo Nordisk also filed a separate application for a 25 mg Ozempic tablet for type 2 diabetes, with an FDA decision expected by the end of 2026. A 25 mg oral semaglutide already exists for weight management under the Wegovy® tablet brand — different indication, different dosing path.
For the rest of this comparison, when we say “Rybelsus” we are talking about the oral semaglutide medicine — whether your bottle says Rybelsus today or Ozempic tablets next refill. The clinical data cited below was generated under the Rybelsus name and applies to the same active ingredient.
Mounjaro vs Rybelsus: The real differences
Answer capsule
Mounjaro is tirzepatide, a once-weekly injection that activates two gut hormone receptors (GLP-1 and GIP). Rybelsus / Ozempic tablets is semaglutide, a once-daily oral tablet that activates one receptor (GLP-1). Mounjaro is FDA-approved for type 2 diabetes in adults and kids 10 and up. Rybelsus is FDA-approved for type 2 diabetes in adults and — uniquely — for cutting the risk of major heart attack, stroke, or cardiovascular death in high-risk type 2 diabetes patients.
These are not the same drug in different packages. They are different active ingredients made by different companies, with different mechanisms and different track records.
| Category | Mounjaro | Rybelsus / Ozempic tablets |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Made by | Eli Lilly | Novo Nordisk |
| Drug class | Dual GIP / GLP-1 receptor agonist | GLP-1 receptor agonist |
| Form | Once-weekly subcutaneous injection (single-dose pen) | Once-daily oral tablet |
| FDA-approved for diabetes | Yes (adults + age 10+) | Yes (adults) |
| FDA-approved for cardiovascular risk reduction | Not yet | Yes (high-risk T2D adults) |
| FDA-approved for weight loss | No | No |
| Doses (US) | 2.5, 5, 7.5, 10, 12.5, 15 mg/week | Rybelsus: 3, 7, 14 mg/day · Ozempic tablets: 1.5, 4, 9 mg/day |
| Dosing rules | Any time of day, with or without food | Empty stomach, ≤4 oz water, wait 30 min before food/drink/other meds |
| Manufacturer list price | $1,112.16 per fill (1-month supply, 4 pens) | Rybelsus: $997.58 per package (NovoCare list) |
GLP-1 = glucagon-like peptide-1, a gut hormone that helps regulate blood sugar and appetite. GIP = glucose-dependent insulinotropic polypeptide, a second gut hormone Mounjaro adds to the mix that semaglutide does not touch.
Want to check whether insurance can cover your GLP-1? Ro's free GLP-1 Insurance Coverage Checker gives a personalized coverage report for FDA-approved options including Ozempic, Wegovy, and Zepbound — best if you are comparing insurance-covered options. Note: Ro does not currently fulfill Mounjaro itself.
Check GLP-1 insurance coverage with Ro → (sponsored affiliate link, opens in a new tab)Is Mounjaro or Rybelsus better for A1C?
Answer capsule
Mounjaro produces a bigger A1C drop than Rybelsus in the available trial data. In SURPASS-2 (40 weeks, 1,879 adults), Mounjaro 15 mg lowered A1C by 2.3 percentage points versus 1.9 points for injectable semaglutide 1 mg. In PIONEER 1 (26 weeks, monotherapy), Rybelsus 14 mg lowered A1C by 1.4 points versus placebo. There is no direct head-to-head trial of Mounjaro vs Rybelsus.
A1C is your average blood sugar over the past two to three months. A 1-point drop is meaningful. A 2-point drop is large.
| SURPASS-2: Mounjaro vs injectable semaglutide 1 mg (40 weeks) | |
|---|---|
| Treatment arm | A1C drop (percentage points) |
| Mounjaro 5 mg | −2.0 |
| Mounjaro 10 mg | −2.2 ✦ |
| Mounjaro 15 mg | −2.3 ✦ |
| Injectable semaglutide 1 mg | −1.9 |
| ✦ Statistically significant versus semaglutide 1 mg. Source: Frías et al., NEJM 2021 and Mounjaro DailyMed label. | |
| PIONEER 1: Rybelsus monotherapy vs placebo (26 weeks) | |
|---|---|
| Treatment arm | A1C drop (percentage points) |
| Rybelsus 7 mg | −1.2 |
| Rybelsus 14 mg | −1.4 |
| Placebo | −0.3 |
| Source: Aroda et al., Diabetes Care, 2019; Rybelsus DailyMed label. | |
The honest catch
Oral semaglutide has an estimated absolute bioavailability of about 0.4%–1% for Rybelsus 3/7/14 mg and 1%–2% for the new Ozempic tablets 1.5/4/9 mg. Most of the dose is broken down in the stomach. That is why the 14 mg Rybelsus tablet produces lower semaglutide blood levels than the 1 mg injection studied in SURPASS-2 — and why the real-world A1C gap between Mounjaro and oral semaglutide is probably bigger than the cross-study comparison suggests.
Practical takeaway: If your prescriber's main goal is getting your A1C down hard, Mounjaro is the stronger conversation to have. If A1C is borderline and convenience matters more, Rybelsus / Ozempic tablets can still get the job done.
Which causes more weight loss — and what if I am here for weight loss only?
Answer capsule
Mounjaro produces about three times more weight loss than Rybelsus in the trial data — 11.2 kg (24.7 lb) on Mounjaro 15 mg over 40 weeks (SURPASS-2) vs 3.7 kg (8.1 lb) on Rybelsus 14 mg over 26 weeks (PIONEER 1). But here is the part most pages will not tell you straight: neither drug is FDA-approved for weight loss. If shedding pounds is your goal — not managing diabetes — you should be comparing different brands.
A huge chunk of people typing “Mounjaro vs Rybelsus” into a search bar are not comparing them for diabetes. They are comparing them for weight loss. And if weight loss is your actual goal, here is what is actually FDA-approved:
| You want… | The right FDA-approved brand | Notes |
|---|---|---|
| Tirzepatide for weight loss | Zepbound | Same weekly shot as Mounjaro, indicated for chronic weight management. LillyDirect Self Pay vials: $299–$449/mo. |
| Semaglutide for weight loss (injection) | Wegovy | NovoCare cash pay starting at $199–$349/mo. |
| Semaglutide for weight loss (pill) | Wegovy tablets (oral 25 mg) | OASIS-4 trial reported ~16.6% mean weight loss. |
| A new oral pill that isn't semaglutide | Foundayo (orforglipron) | FDA-approved April 1, 2026. First oral non-peptide GLP-1. No food or water restrictions. |
The math is brutal for off-label prescribing. If you take Mounjaro for weight loss without a diabetes diagnosis, insurance almost always denies it. Self-pay pricing for the correctly indicated drug is dramatically lower. Picking the right indication is also the cleaner play if you ever need to fight an insurance denial later.
Our free quiz asks about your goal, insurance, state, and budget, then matches you to the right FDA-approved medication and the telehealth path that actually carries it.
Take the free 60-second matching quiz →Which is easier to take: the weekly shot or the daily pill?
Answer capsule
It is not as obvious as it sounds. Mounjaro is once a week, any time of day, with or without food. Rybelsus requires an empty stomach, four ounces of plain water max, and a 30-minute wait before food, drinks, coffee, or any other oral medication. If your morning routine is rigid and quiet, the pill is fine. If your morning is chaos, the weekly shot is genuinely easier despite the needle.
Mounjaro convenience profile
- ✓One injection per week
- ✓Any day, any time
- ✓With or without food
- ✓Rotate sites between abdomen, thigh, upper arm
- ✓Pre-loaded pen with hidden needle
- ✓~30 seconds of training to use it
Rybelsus / Ozempic tablets convenience profile
- •One tablet every day
- •Empty stomach (typically first thing in the morning)
- •Up to 4 oz of plain water — no coffee, no juice
- •Wait at least 30 min before eating, drinking, or taking other oral meds
- •Do not split, crush, chew, or dissolve the tablet
- •Coffee inside the 30-min window reduces absorption
| If this is you | Easier fit |
|---|---|
| I will not inject myself, end of conversation | Rybelsus / Ozempic tablets |
| I forget morning routines all the time | Mounjaro |
| I take 3 other meds in the morning | Mounjaro (timing rules clash) |
| I travel a lot and packing pens is annoying | Rybelsus / Ozempic tablets |
| I have kids/pets/a chaotic morning | Mounjaro |
| I value once-and-done weekly dosing | Mounjaro |
Because oral semaglutide bioavailability is so low, the SNAC absorption enhancer only works under those exact stomach conditions. Break the rules, and you are not getting the dose you think you are getting.
How much do Mounjaro and Rybelsus actually cost in 2026?
Answer capsule
Mounjaro's manufacturer list price is $1,112.16 per fill (a 1-month supply of 4 pens). NovoCare lists Rybelsus at $997.58 per package. Almost nobody pays full list. The real number depends on insurance coverage and savings program eligibility. The cheapest legitimate cash-pay path right now is the new Ozempic tablets through NovoCare Pharmacy at $149–$299/month. Mounjaro does not have a manufacturer cash-pay program.
Verified pricing matrix (last verified )
| Path | Mounjaro | Rybelsus / Ozempic tablets |
|---|---|---|
| Manufacturer list price | $1,112.16 per fill | $997.58 per package |
| Savings card — commercial insurance covers drug | As little as $25 for up to a 3-month Rx | As little as $25 per fill (max $100/$200/$300 for 1/2/3-month supply) |
| Savings card — commercial insurance, drug NOT covered | As low as $499 for a 1-month fill | Offer requires product coverage; not designed for non-covered plans |
| Manufacturer direct cash pay (no insurance) | None for Mounjaro itself | NovoCare: $149 (1.5 mg) / $199 (4 mg) / $299 (9 mg) — self-pay only; government beneficiaries excluded |
| Retail cash + GoodRx discount | ~$995–$1,200/month | ~$850–$995/month |
| Medicare Part D (T2D only) | Plan-specific copay; manufacturer card not allowed | Plan-specific copay; manufacturer card not allowed |
The single cheapest legitimate brand-name path right now
If you have no insurance and want oral semaglutide, Ozempic tablets through NovoCare Pharmacy at $149/$199/$299 per month is the cheapest manufacturer-direct cash path available for either of these drugs. Mounjaro itself has no equivalent program — but if your real goal is weight loss, Zepbound vials through LillyDirect run $299–$449/month (same active ingredient, FDA-approved for obesity).
Ro's free GLP-1 Insurance Coverage Checker gives a personalized coverage report for FDA-approved options including Ozempic, Wegovy, and Zepbound. The concierge team handles prior authorization paperwork. Membership: $39 first month, then as low as $74/month with annual plan.
Check GLP-1 insurance coverage with Ro → (sponsored affiliate link, opens in a new tab)Which has more side effects or safety concerns?
Answer capsule
Both medicines carry the same FDA boxed warning for thyroid C-cell tumor risk, both are contraindicated if you or close family have medullary thyroid carcinoma (MTC) or MEN 2, and both can cause significant gastrointestinal side effects. Rybelsus's label reports GI adverse events in about 32% of patients on 7 mg and 41% on 14 mg versus 21% on placebo. Mounjaro's most common GI side effect is nausea — about 12% at 5 mg, 15% at 10 mg, 18% at 15 mg in the pooled placebo-controlled adult trials.
FDA Boxed Warning — both drugs
Animal studies showed thyroid tumors. Human risk is unknown but not zero. Do not use either drug if you or a close family member has medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
GI side effects — what the labels actually report
| Metric | Rybelsus (PIONEER trials) | Mounjaro (pooled adult T2D trials) |
|---|---|---|
| GI adverse events | ~32% at 7 mg / ~41% at 14 mg | Nausea: 12% at 5 mg / 15% at 10 mg / 18% at 15 mg |
| Placebo GI rate | ~21% | Lower comparator |
| Discontinuation due to GI | ~4% at 7 mg / ~8% at 14 mg | GI effects most intense during 4-week titration steps |
| Most common symptoms | Nausea, abdominal pain, diarrhea, vomiting, decreased appetite | Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion |
Other serious risks (both drugs)
- •Pancreatitis — severe stomach pain that may shoot to your back. Stop and call your doctor.
- •Vision changes — especially when blood sugar drops fast in T2D patients.
- •Hypoglycemia — low blood sugar, much more likely if you also take insulin or sulfonylureas.
- •Gallbladder problems — gallstones, inflammation.
- •Acute kidney injury — usually triggered by dehydration from severe vomiting or diarrhea.
- •Possible ileus — slowed or blocked intestinal contents (post-marketing reports).
- •Allergic reactions including angioedema — swelling of face, lips, tongue.
Two specific safety points most pages skip
Mounjaro can lower oral birth control effectiveness. The Mounjaro label warns that oral hormonal contraceptives may not work as reliably for 4 weeks after starting Mounjaro and 4 weeks after each dose increase. If you use the pill as your primary birth control, you will need to switch to a non-oral method or add a barrier method during those windows.
Rybelsus has specific data on diabetic retinopathy complications. If you have existing diabetic eye disease, this is a conversation to have with your prescriber before starting.
Who should consider Mounjaro?
Answer capsule
Mounjaro is the better fit when you have type 2 diabetes, your priority is the largest A1C and weight effect available in the GLP-1 class, you can use a once-weekly injection, and your access path works. It is also the cleaner conversation if a strict daily pill routine is not realistic for your life.
Mounjaro probably fits if:
- ✓A1C is your main problem and you want it down hard
- ✓You want significant weight reduction alongside T2D management
- ✓A weekly shot does not bother you
- ✓You have commercial insurance covering tirzepatide, OR
- ✓You can pay $499–$1,112 cash and consider it worth it
- ✓You do not use oral birth control as your primary contraception
Mounjaro probably does not fit if:
- ✗Needles are a hard no
- ✗You do not have coverage and the cash math does not work
- ✗You have a personal/family history of MTC or MEN 2
- ✗Your real goal is weight loss without T2D — look at Zepbound instead
- ✗You want the cheapest possible cash-pay path right now
Want to discuss Mounjaro with a provider?
Sesame Care's network of providers can prescribe Mounjaro for type 2 diabetes when clinically appropriate. Mounjaro pens can range from $1,080 to $1,300/month without insurance depending on your pharmacy. Providers may assist with prior authorization. Medication cost is separate from your visit cost.
Who should consider Rybelsus / Ozempic tablets?
Answer capsule
Rybelsus / Ozempic tablets is the better fit when needles are a real barrier, your morning routine can support the empty-stomach rules, you want the cheapest current cash-pay path through NovoCare Pharmacy ($149–$299/month), or you have type 2 diabetes plus established cardiovascular disease and want the only oral GLP-1 with FDA-approved cardiovascular risk reduction labeling.
Rybelsus / Ozempic tablets probably fits if:
- ✓You won't or can't inject yourself
- ✓Your mornings are predictable and quiet enough to wait 30 minutes before eating
- ✓You are uninsured and want a transparent cash price ($149/$199/$299)
- ✓You have T2D plus heart disease, prior heart attack/stroke, or chronic kidney disease
- ✓Modest A1C improvement is enough; you do not need the maximum
Rybelsus / Ozempic tablets probably does not fit if:
- ✗Your A1C is severely uncontrolled and you need the strongest available drug
- ✗You take multiple morning medications that can't wait 30 minutes
- ✗You travel constantly and meal timing is unpredictable
- ✗Your goal is weight loss — look at Wegovy or Wegovy tablets instead
- ✗You have a personal/family history of MTC or MEN 2
Ro's free GLP-1 Insurance Coverage Checker gives a personalized coverage report for FDA-approved options including Ozempic, Wegovy, and Zepbound. Prior-auth concierge included.
Cardiovascular risk: the one place Rybelsus clearly wins
Answer capsule
As of October 2025, Rybelsus (and now Ozempic tablets) is the only oral GLP-1 medicine FDA-approved to reduce the risk of major cardiovascular events — heart attack, stroke, or cardiovascular death — in adults with type 2 diabetes who have established heart disease, chronic kidney disease, or both. The approval is based on the SOUL trial, which showed a 14% reduction in major adverse cardiovascular events over ~4 years versus placebo. Mounjaro does not yet carry this indication.
If you have type 2 diabetes plus any of these, bring it up with your prescriber:
- •Established coronary heart disease
- •History of heart attack or stroke
- •Symptomatic peripheral artery disease
- •Chronic kidney disease
The SOUL trial enrolled 9,650 patients aged 50+ over 3.5–5 years. The 14% relative risk reduction translated to about a 2% absolute reduction by year 3. Sources: SOUL trial published in NEJM; FDA approval October 17, 2025. This is a reason to bring the topic up with your doctor if your cardiovascular risk profile is elevated — not a reason to self-select Rybelsus over Mounjaro without clinical guidance.
Can you switch from Rybelsus to Mounjaro?
Answer capsule
Yes, under prescriber supervision. Mounjaro's labeled starting dose is 2.5 mg once weekly for 4 weeks — that starter dose is not intended for glycemic control, it is there to reduce GI side effects. Your prescriber decides the switching plan: when to stop the oral, when to start the injection, and how to monitor blood sugar during the transition.
Real questions from patients about this exact switch:
“Do I need to wait to make the switch between Rybelsus and Mounjaro?”
“My doctor said I needed to wait a week, my pharmacist said to wait 2 days. Now I'm just confused.”
What to ask your prescriber before switching:
- →What dose of Mounjaro do I start on?
- →Do I stop Rybelsus before starting Mounjaro, or overlap?
- →How should I monitor my blood sugar during the switch?
- →Will my insulin or sulfonylurea dose need to come down to avoid hypoglycemia?
- →What side effects should make me call you?
- →Does my insurance need a prior authorization for Mounjaro?
- →When should I expect to feel the effect?
Read our full semaglutide-to-tirzepatide switching guide for the prescriber conversation script and sample timelines:
How to Switch from Semaglutide to Tirzepatide →Can you take Mounjaro and Rybelsus together?
Short answer: Do not combine them on your own.
Both are GLP-1 receptor agonists with overlapping risks including GI adverse events and hypoglycemia when used with insulin or sulfonylureas. There is no well-designed clinical case for stacking two drugs that target the same receptor pathway. If a clinician is recommending both, ask them to explain why and whether one is supposed to replace the other.
Where to actually get a prescription online
Answer capsule
For Mounjaro specifically, Sesame Care is the better path — Sesame's provider network can prescribe Mounjaro for type 2 diabetes. For Rybelsus / Ozempic tablets, NovoCare Pharmacy direct is the cheapest cash-pay option ($149/$199/$299/mo) for self-pay patients. For coverage checks, prior authorization help, and any FDA-approved weight-loss alternative (Zepbound, Wegovy, Foundayo), Ro is the strongest choice.
Sesame Care
Best for Mounjaro- ✓Provider network can prescribe Mounjaro for type 2 diabetes when clinically appropriate
- ✓Provider choice — you pick from real licensed clinicians
- ✓Transparent visit pricing
- ✓Wide formulary: Mounjaro, Wegovy, Zepbound, Ozempic, Saxenda
- ✓Providers may assist with prior authorization
Important: Medication cost is separate from your Sesame visit cost. Mounjaro pens can range from ~$1,080 to $1,300/month at retail without insurance.
Compare Sesame providers for a GLP-1 visit → (sponsored affiliate link, opens in a new tab)Ro
Best for insurance checks & weight-loss alternatives- ✓Free GLP-1 Insurance Coverage Checker — personalized coverage report
- ✓Insurance concierge that submits prior authorization paperwork
- ✓Carries Wegovy, Wegovy tablets, Zepbound, Zepbound KwikPen, Foundayo
- ✓Membership: $39 first month, then as low as $74/month with annual plan
Note: Ro publicly states it does not currently offer Mounjaro. If Mounjaro is what you want specifically, use Sesame Care.
Check coverage with Ro's free GLP-1 tool → (sponsored affiliate link, opens in a new tab)NovoCare Pharmacy
Best for lowest cash price on Ozempic tablets- ✓Direct from Novo Nordisk — transparent flat pricing by dose
- ✓$149 (1.5 mg) / $199 (4 mg) / $299 (9 mg) per month
- ✓Self-pay only — Medicare, Medicaid, TRICARE, and VA excluded
- ✓Ships to home — you still need a valid US-licensed prescriber
What about Medicare?
Answer capsule
Medicare Part D plans can cover Mounjaro and Rybelsus / Ozempic tablets for type 2 diabetes, but Medicare patients cannot use the manufacturer savings cards, and the new Ozempic tablet cash-pay offer excludes government beneficiaries. The Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027, for eligible beneficiaries and certain GLP-1 drugs.
- •Coupon math does not apply. If you see "$25/month with savings card," that is not for you.
- •The cheapest cash-pay options from manufacturers are designed for non-government-insured patients.
- •The Medicare GLP-1 Bridge may help if you qualify and your medication is on the list — your prescriber and pharmacy can verify when it goes live.
Which one may fit you? A simple decision guide
Use this as a conversation starter, not a prescription. Talk with a licensed clinician.
What we actually verified for this page
Answer capsule
Every commercial number and clinical claim on this page was checked against a primary source on . We do not accept manufacturer payments to influence editorial. Affiliate income from telehealth providers does not change which medication we recommend or which clinical numbers we report.
| Claim | Primary source |
|---|---|
| Mounjaro list price ($1,112.16/fill) | Lilly pricing info page |
| Mounjaro Savings Card terms | Lilly savings page |
| Mounjaro FDA label (indications, dosing, warnings, side effects) | Mounjaro DailyMed label |
| Rybelsus list price ($997.58/package) | NovoCare list price page |
| Rybelsus / Ozempic tablets FDA label | DailyMed Ozempic / Rybelsus label |
| Rybelsus → Ozempic tablet rebrand and dose mapping | Novo Nordisk PR Newswire May 1, 2026 |
| Ozempic tablet cash-pay pricing ($149/$199/$299) | Novo Nordisk PR; GoodRx-Novo Nordisk partnership announcement May 2026 |
| Government beneficiary exclusion | Novo Nordisk PR Newswire May 1, 2026 |
| SURPASS-2 results | Frías et al., NEJM 2021; Mounjaro DailyMed label |
| PIONEER 1 results | Aroda et al., Diabetes Care 2019; Rybelsus DailyMed label |
| SOUL trial / FDA CV-risk indication | Novo Nordisk Oct 17, 2025 release; FDA approval |
| Foundayo approval Apr 1, 2026 | FDA press release |
| Zepbound LillyDirect self-pay pricing | Lilly Zepbound pricing announcement |
| Novo Nordisk planned Jan 1, 2027 list price reduction | Novo Nordisk PR Newswire Nov 2025 |
| Medicare GLP-1 Bridge dates and structure | CMS Medicare GLP-1 Bridge program page |
Mounjaro vs Rybelsus FAQ
Is Mounjaro better than Rybelsus?
For A1C reduction and weight loss, Mounjaro produces a larger effect in the available trial data — A1C drop of 2.3 points vs 1.4 points, weight loss of 11.2 kg vs 3.7 kg at top doses. For cardiovascular risk reduction in high-risk type 2 diabetes patients, Rybelsus (and Ozempic tablets) is the only oral GLP-1 with that FDA indication. Better depends on which goal matters most for you.
Is Rybelsus the same as Ozempic tablets?
Effectively yes. Both are oral semaglutide made by Novo Nordisk. Starting May 4, 2026, Novo Nordisk launched Ozempic tablets in the US with reformulated doses (1.5 mg, 4 mg, and 9 mg) replacing the Rybelsus brand domestically. The active ingredient is the same. The two are not milligram-to-milligram interchangeable. Rybelsus continues to be sold under that name outside the US.
Is Ozempic tablets the same as Rybelsus or Wegovy tablets?
Ozempic tablets and Rybelsus are oral semaglutide formulations approved for type 2 diabetes. Wegovy tablets are oral semaglutide approved for chronic weight management at a higher 25 mg dose. Same active ingredient family, different doses, different FDA indications.
Is Rybelsus being discontinued?
In the US, the Rybelsus brand is being replaced by Ozempic tablets starting May 4, 2026. Current Rybelsus patients should keep taking their medication as directed and discuss transitioning to Ozempic tablets at their next refill with their prescriber. Rybelsus continues to be marketed outside the US.
Which is cheaper, Mounjaro or Rybelsus?
At list price, Rybelsus is cheaper ($997.58 per package vs Mounjaro at $1,112.16 per fill). For uninsured cash-pay patients who are not on government insurance, Ozempic tablets through NovoCare Pharmacy is dramatically cheaper at $149, $199, or $299 per month depending on dose. Mounjaro does not have a manufacturer cash-pay program.
Can I switch from Rybelsus to Mounjaro?
Yes, under prescriber supervision. Mounjaro's labeled starting dose is 2.5 mg once weekly for the first 4 weeks — that starter dose is not intended for glycemic control, it is there to reduce GI side effects. The timing of when to stop the oral and start the injection depends on your current dose, other diabetes medications, and tolerance, and should be set by your prescriber.
Can I take Mounjaro and Rybelsus together?
Do not combine them on your own. Both are GLP-1 receptor agonists with overlapping risks. If a clinician is recommending both, ask them to explain why and whether one is intended to replace the other.
Is Mounjaro or Rybelsus FDA-approved for weight loss?
Neither. Mounjaro is approved for type 2 diabetes. Rybelsus and Ozempic tablets are approved for type 2 diabetes and cardiovascular risk reduction in high-risk T2D patients. The FDA-approved brands for weight loss are Zepbound (tirzepatide), Wegovy (semaglutide), Wegovy tablets (oral semaglutide 25 mg), and Foundayo (orforglipron, approved April 1, 2026).
How much weight will I lose on Mounjaro vs Rybelsus?
In trials: about 11.2 kg (24.7 lb) on Mounjaro 15 mg over 40 weeks (SURPASS-2), versus about 3.7 kg (8.1 lb) on Rybelsus 14 mg over 26 weeks (PIONEER 1). These are different studies with different designs, so the comparison is not perfect — but the gap is consistent across the data. Individual results vary.
Does Medicare cover Mounjaro or Rybelsus?
Medicare Part D plans can cover both medicines for type 2 diabetes, but Medicare patients cannot use the manufacturer savings cards and are excluded from the Ozempic tablet cash-pay offer. Off-label use for weight loss is typically not covered. The Medicare GLP-1 Bridge program runs July 1, 2026 to December 31, 2027 and may expand access for eligible patients on certain GLP-1 drugs.
What's the worst side effect of each?
For both: thyroid C-cell tumor risk (FDA boxed warning), pancreatitis, gallbladder problems, hypoglycemia especially with insulin or sulfonylureas, kidney injury from dehydration, and vision changes. Mounjaro additionally can reduce the effectiveness of oral hormonal birth control for 4 weeks after starting and after each dose increase.
Will my Rybelsus prescription still work after May 4, 2026?
Yes. Keep taking your current prescription exactly as directed. Talk to your prescriber before your next refill about transitioning to Ozempic tablets at the bioequivalent dose. Rybelsus 7 mg patients may transition to Ozempic tablets 4 mg, and Rybelsus 14 mg patients may transition to Ozempic tablets 9 mg. Do not switch on your own.
Still not sure which GLP-1 program is right for you?
You have now seen the side-by-side. The trial numbers. The cost paths. The honest disclosure that neither drug is the right answer for weight-loss-only intent.
The free quiz asks about:
- →Whether your goal is type 2 diabetes management, weight loss, cardiovascular protection, or all three
- →Insurance status (commercial, Medicare, Medicaid, none, not sure)
- →Injection vs pill preference
- →State (some providers don't prescribe in every state)
- →Budget reality
More from The RX Index
- →Mounjaro vs Ozempic 2026: Verdict, Cost, A1C — The other comparison Mounjaro shoppers usually look at
- →Best GLP-1 for Diabetes: Blood Sugar, Heart & Cost — The broader diabetes ranking
- →How to Switch from Semaglutide to Tirzepatide — Full prescriber conversation script
About this page
- Created by:
- The RX Index Editorial Team
- About The RX Index:
- A pricing intelligence and comparison resource for GLP-1 telehealth providers.
- How this was produced:
- We compared current FDA-label information from DailyMed, manufacturer pricing pages, primary-source clinical trial publications (NEJM, Diabetes Care), and current telehealth provider pages, all verified .
- Affiliate disclosure:
- We earn a commission if you click certain links and start treatment with a provider. That commission does not change which medication we recommend, which clinical data we cite, or which provider we route you to for your specific need. We route Mounjaro searchers to Sesame because Ro does not currently fulfill Mounjaro — even when Ro pays better — because that is the honest answer.
- Last verified: